The most diverse health care company in the world has an impressive and growing portfolio of biologic medicines -- and the future just got brighter. Johnson & Johnson (NYSE:JNJ) recently announced that Stelara, one of its fastest growing therapies, received a positive opinion for treating psoriatic arthritis from the European Medicine Agency's Committee for Medicinal Products for Human Use, or CHMP. The disease affects nearly 4.2 million people across Europe.
While an expanded indication is still pending approval, what would it mean for the European market? Can Stelara beat out incumbent therapies such as Enbrel and Humira? Fool contributor Maxx Chatsko analyzes the situation in the following video.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.
The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.